The Non-animal Alternative Testing Market Projected to Grow at a CAGR of 13.48% and Generate a Revenue of $29,390.3 million by 2030

The global non-animal alternative testing market size is predicted to be valued at $29,390.3 million by 2030, surging from $9,806.6 million in 2021, at a noteworthy CAGR of 13.48%.

COVID-19 Impact on Non-animal Alternative Testing Market

The emergence of COVID-19 pandemic has demonstrated to have a good influence on non-animal alternative testing market expansion. As the impact of COVID-19 pandemic has had a devastating impact on the health and wellbeing of the people around the globe, the fear of getting infected by coronavirus and its terrible symptoms has settled in the people. To find the cure of the virus, the availability of test subjects such as animals was very low and having a better alternative such as computer simulated program and Organs-on-chips (OOCs) tool for testing is a major trend in the non-animal alternatives testing market. Organs-on-chips are miniature tissues and organs grown in-vitro that enable the modeling of human physiology and disease. The increase in the market for testing non-animal alternatives is primarily attributable to businesses starting up again and adjusting to the new normal as they recover from the COVID-19 effect, which had previously resulted in restrictive containment measures such as social isolation, remote work, and closure of commercial activities that created operational difficulties.

Global Non-animal Alternative Testing Market Analysis

There are several researches involving drug testing that are in continuous progression and immense need for drug to be tested as companies are ambitious to find the potential drug candidate. This opens doors for the alternative methods such as using in silico and organ on chip method which does not involve animals. Similar research programs to promote non-animal testing procedures are also initiated by countries such as Denmark, Brazil, Germany, Switzerland, Australia, China, and Korea. The constant support from the government of these countries is expected to drive growth of the non-animal testing market.

Cell cultures lack any connection to a central nervous system, endocrine system, and immune system. There is possibility of getting deviated results of reaction in cell culture and organs in the body. The technological advancements are difficult for many scientist to adopt.

Both the medical and pharmaceutical industries, who are concentrating on making medicines, have been interested in OOCs due to their benefits over cell culture, animal models, and human clinical trials. For instance, researchers at the Massachusetts Institute of Technology (MIT) in the U.S., created a novel concept for Organs-on-chip to investigate therapies for inflammatory illnesses and ailments in April 2020. Organs-on-chip are devices made of millions of cells that mimic the functioning of several organs. They may be used to study complicated diseases and develop new therapies without using animals in testing.

Global Non-animal Alternative Testing Market Share, Segmentation

The global non-animal alternative testing market is segmented based on technology, method, end-user, and region.

Technology:

The global non-animal alternative testing market by technology is segmented into cell culture technology, high throughput technology, molecular imaging, and omic technology. The cell culture technology sub-segment is projected to generate maximum revenue and the omic technology sub-segment is expected to register the fastest growth by 2030, with an increase from $11,025 million in 2021 to $3,845.5 million in the forecasting years. Cell culture technology sub-segment is growing as the researchers widely use cell culture technology to analyze large number of test results in a single run. The omic technology sub-segment registers growth due to detailed analysis on the human cell and drug interaction which increases non animal alternative testing market size.

Method:

The global non-animal alternative testing market by method is segmented into cellular assay, biochemical assay, in silico, and ex-vivo. The cellular assay sub-segment is projected to generate maximum revenue and the ex-vivo sub-segment to generate fastest growth. Cellular assay is more preferred because it is used for analyzing large amount of human cellular data during pre-clinical trials. The increase in the revenue of ex-vivo sub-segment owes to the rapidly rising demand for artificial organs in cosmetic industry to test the sensitivity of product. These factors are increasing the non-animal alternative testing market value.

End-user:

The global non-animal alternative market by end-user is segmented into pharmaceutical industry, cosmetics & household products, diagnostics, chemical industry, and food industry. The pharmaceutical industry sub-segment is projected to generate maximum revenue and the chemical industry sub-segment is expected to register the fastest growth. Increasing ban on use of animals for drug testing has further encouraged the market players to use silico drug testing methods to avoid any kind of ethical issues such as experimenting on animals for checking the effectiveness of medicine, which is boosting the pharmaceutical industry sub-segment. The efficacy & sensitivity of chemicals must be tested first before administrating or using it on human which is projected to drive the chemical industry segment growth.

Region:

The non-animal alternative testing market was investigated across North America, Europe, Asia-Pacific, and LAMEA. The non-animal alternative testing market share in North America to be the most dominant. North America market accounted $4,216.8 million in 2021 and is projected to register a revenue of $12,020.6 million by 2030. The Asia-Pacific non-animal alternative testing market is expected to observe fastest growth and register a revenue of $4,878.8 million by 2030 in the forecasting period. Increasing number of research facilities in Asia-Pacific region is driving the growth and rising geriatric population is boosting the growth in North America.

Key Players in the Global Non-animal Alternative Testing Market

Some of the leading non-animal alternative market players are 

1. VITROCELL Systems GmbH
2. Evotec SE
3. Biovit
4. MB Research Laboratories
5. Emulate, Inc
6. TARA Biosystems, Inc.
7. Bio-Rad Laboratories, Inc.
8. Abbott
9. Hurel Corporation
10. TissUse GmbH.

In 2018, Emulate was funded an amount of $36 million from its founder's fund and ALS Investment Fund, SciFi VC, GlassWall Syndicate Association to extend its biological capabilities to Liver-Chip, Intestine-Chip, Lung-Chip, and Brain-Chip, and to its human-relevant models of thrombosis and immune system modulation. ALS Investment Fund, SciFi VC and GlassWall Syndicate Association are venture capital and private equity firm that supports and finances biotech companies.